Immunic

Dr. Duane Nash resigned from Immunic’s supervisory board effective September 10, 2026. The company said the resignation was not related to any disagreements over the company’s operations, policies or practices. As a result of his departure, the number of supervisory board members will be reduced from ten to nine; the notice is based on a Form 8‑K filed with the SEC. » Więcej na de.investing.com

Immunic has appointed Elena Ridloff to the board of directors with immediate effect. Ridloff brings more than 20 years of experience in finance, corporate development and capital markets in the biopharma industry, currently serving as CFO of Sionna Therapeutics and as a board member at Kymera Therapeutics. The appointment comes ahead of the expected top-line data from the phase-3 trials of Vidofludimus-Calcium in relapsing multiple sclerosis and before the planned initiation of a confirmatory phase-3 program for progressive MS. » Więcej na de.investing.com

Immunic named Erik Lundgren CEO effective May 22, 2026, with his employment starting June 1; he succeeds Daniel Vitt who will remain on the board and continue to oversee scientific strategy and portfolio advancement. Lundgren brings nearly two decades of commercial and multiple sclerosis experience from Genentech and Roche, including work on the launch of Ocrevus. He will lead advancement of vidofludimus calcium through the pivotal phase 3 ENSURE trial in relapsing MS, a planned phase 3 program in primary progressive MS, and preparations for regulatory filings and potential commercialization. The company granted Lundgren an equity option to purchase 1 million shares under its 2026 inducement plan. » Więcej na finance.yahoo.com